
HERZLIYA, Israel and CALGARY, AB, Jan. 29, 2025 — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a leading innovator in pharmaceuticals and biotechnology, reports that its subsidiary, BI Sky Global (BI), successfully completed Human Repeated Insult Patch Testing (HRIPT) for sensitization and irritation, confirming the safety of its cosmetic products. HRIPT is the industry standard safety test for cosmetics, over-the-counter drugs, and topical medical devices.

The Company also announced exceeding a key sales target: an average of 5,000 units sold daily in 2024. This is noteworthy because 5,000 units is the typical minimum production run for most cosmetic products; BI Sky Global achieves this daily. This substantial sales volume surpasses the requirements for annual production contracts with major third-party manufacturers.
“Successfully completing HRIPT testing and achieving daily sales of 5,000 units demonstrates our commitment to high-quality, in-demand products,” stated Roni Kamhi, CEO of BI Sky Global. “This positions us for growth in sales and marketing as we leverage our success and deliver premium products.”
Iris Bincovich, Innocan Pharma’s CEO, added: “This clearly shows how BI Sky Global’s strong performance benefits our shareholders.”
About Innocan
Innocan is a leader in pharmaceuticals and wellness. In pharmaceuticals, Innocan developed a CBD-based liposomal drug delivery system offering precise dosing and controlled release of synthetic CBD for non-opioid pain management. In wellness, Innocan develops and markets a range of high-performance self-care and beauty products promoting healthier lifestyles. This segment operates through its 60%-owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.
For further information, please contact:
Iris Bincovich, CEO
+1-516-210-4025
+972-54-3012842
+44 203 769 9377
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Cautionary note regarding forward-looking information
This news release contains forward-looking information, including information about research and development, collaborations, regulatory applications, future milestones, treatment potential, therapeutic effects, regulatory approvals, and market entry timing. Forward-looking information is inherently uncertain and subject to various risks, some beyond Innocan’s control. This information is based on Innocan’s expectations and assumptions regarding product benefits, regulatory compliance, and production and distribution arrangements.
Several factors could cause actual results to differ materially from forward-looking information, including general economic conditions, government regulations, and relationships with suppliers, manufacturers, customers, partners, and competitors. Product distribution risks include import/export issues and the timely securing of necessary approvals and product availability. The market entry timeline could change due to regulatory requirements or manufacturing/distribution delays. Readers should not over-rely on forward-looking information regarding product launch timing. Additional risks are detailed in Innocan’s public filings.
Readers are cautioned not to place undue reliance on forward-looking information. Innocan does not undertake to update forward-looking information, except as required by law.
Logo –
SOURCE Innocan Pharma Corporation